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Sammanfattning  
 
Blåbär (Vaccinium myrtillus) har ett högt innehåll av fenoler (flavonoider och fenolsyror). 
Vissa av dessa fenoler har visats metaboliseras i levern av cytokrom P450, ett enzymatiskt 
system vilket även är har en huvudsaklig roll gällande metaboliseringen av läkemedel. Det 
har rapporterats att ett flertal flavonoler (en flavonoid subgrupp), så som quercetin, myrice-
tin, isorhamnetin och rutin har interagerat med CYP450, t.ex. via inhibering. Inhibering av 
CYP450 kan antingen öka eller minska effekten av läkemedel. Därav bör interaktioner mel-
lan blåbär och metabolisering av läkemedel närmare studeras. Skillnader i metabolism mel-
lan män och kvinnor bör också studeras i.o.m. att CYP450 gener uttrycks olika hos män och 
kvinnor. Mikrosomer från levern är användbara i in vitro-modeller, vilka ofta tillämpas i ett 
tidigt skede av läkemedelsutvecklingsprocessen, då för att identifiera potentiella interakt-
ioner mellan läkemedel och livsmedel samt mellan läkemedel och läkemedel. På grund av 
likheterna mellan gris och människa med avseende på CYP450 i lever samt på grund av den 
stora tillgängligheten av grislever via slakterier, har mikrosomer från gris blivit en attraktiv 
model i biokemiska studier av könsrelaterade skillnader i livsmedels-läkemedelsinterakt-
ioner.  
 
Målet för denna studie var att utvärdera om och hur blåbär och fenoliska förningar i blåbär 
inhiberar CYP450 isoform 1A och 3A. Fem flavonoler från blåbär valdes utefter deras pot-
ential att interagera med CYP450. I dagsläget, har inga studier andra studier påträffats avse-
ende blåbär och de valda komponenternas inhiberande effekt på CY1A och CYP3A. Fyra 
fenolsyror som finns i blåbär valdes också ut för att studeras p.g.a. deras antioxidativa kapa-
citeter (som i mycket liknar flavonolernas). Välkända och specifika probe substrat användes 
tillsammans med mikrosomer från svin (entire male and female pigs). Kinetiska mätningar 
utfördes för att utreda inhiberingsmekanism. Potentiella skillnader mellan könen utvärdera-
des.  
 
CYP3A aktivitet inhiberades av myricetin; icke-kompetitivt hos hanar (Ki=112.7) och 
inte alls hos honor, av isorhamnetin; kompetitivt hos hanar (Ki=71.2) och icke-kompetitivt  
hos honor (Ki=93.7). CYP1A aktivitet inhiberades av myricetin; kompetitivt hos hanar 
(Ki=2.5) och hos honor (Ki=4.6), av isorhamnetin; kompetitivt hos hanar (Ki=99.9) och hos 
honor (Ki=10.8), av quercetin; kompetitvt hos hanar (Ki=0.2) och irreversibelt hos honor 
(IC50=1.3). 
 
Resultaten ifrån denna studie indikerar att aktiviteten av CYP450 1A och 3A inhiberas av 
vissa komponenter från blåbär och att detta är en effekt som kan ha könsrelaterade skillnader.  
 
Nyckelord: Cytokrom P450, CYP1A, CYP3A, Blåbär (Vaccinium myrtillus), Läkemedelsin-
teraktioner, Myricetin, Isorhamnetin, Quercetin 
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Abstract   
 
Bilberry fruit (Vaccinium myrtillus) is a rich source of bioactive compounds, including 
flavonols and phenolic acids. At least some of these compounds were shown to be metabo-
lized in the liver by cytochrome P450 (CYP450) enzyme system, which is also important in 
the metabolism of pharmaceuticals. Several flavonols (a flavonoid subgroup) such as quer-
cetin, myricetin, isorhamnetin and rutin have been reported to integrate with CYP450, i.e. 
by inhibition. Thus, a possibility of bilberry interaction with pharmaceutical metabolism 
should be carefully studied. Gender-related differences of such interactions should also be 
considered given that CYP450 genes in male and female are differentially expressed. He-
patic microsomes are useful in vitro model commonly used at early stages of drug develop-
ment to identify potential food-drug or drug-drug interactions. Pig is increasingly used as an 
animal model for human biomedical studies. The comparability of hepatic CYP450 between 
pigs and humans as well as easy availability of porcine livers from abattoirs make porcine 
microsomes an attractive model to study gender-related differences in food-drug interac-
tions.  
 
The aim of this study was to evaluate the inhibitory effect of selected phenolic compounds 
from bilberry fruit on the activities of CYP1A and CYP3A in porcine hepatic microsomes. 
Five flavonols and four phenolic acids were selected for the study. This selection was based 
on two criteria, abundance in bilberry and potential interaction with CYP450. To estimate 
CYP1A and CYP3A activities, the probe substrates 7-ethoxyresorutin and 7-benzyloxy-4-
triflouromethylcoumarin (BFC) were used, respectively.  
 
This study demonstrated that CYP3A activity was non-competitively inhibited by myri-
cetin in male pigs only (Ki=112.7) and-, competitively by isorhamnetin in both male 
(Ki=71.2) and female pigs (Ki=93.7). CYP1A activity was competitively inhibited by my-
ricetin in male (Ki=2.5) and female pigs (Ki=4.6) and by isorhamnetin in male (Ki=99.9) 
and in female pigs (Ki=10.8). Inhibition mode of CYP1A by quercetin differed between 
genders being competitive in male (Ki=0.2) and irreversible in female pigs (IC50=1.3).  
 
In conclusion, this study suggests that the activity of hepatic CYP450 1A and 3A are 
inhibited by the flavonols myricetin, isorhamnetin and querctin. Moreover, this study pro-
vides first evidence of gender-related differences in this inhibition.  
 
Keywords: Cytochrome P450, CYP1A, CYP3A, Bilberry (Vaccinium myrtillus), Food-drug 
interactions, Myricetin, Isorhamnetin, Quercetin 
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 Abbreviations 
 
BBJ Blueberry juice 
BFC 7-Benzyloxy-4-Triflouromethylcoumarin 
BROD Benzyloxyresorufin O-Debenzylase 
BUS Buspiron 
CYP1A Cytochrome P450 1A 
CYP3A Cytochrome P450 3A 
CYP450 Cytochrome P450 
DDI Drug-Drug Interactions  
EROD 7-Ethoxyresorufin O-Deethylase 
ES Enzyme-substrate 
FDI Food-Drug Interactions 
HFC 7-Hydroxy-4-Triflouromethylcoumarin 
IBS Irritable bowel syndrome  
MROD Methoxyresorufin O-Demethylation 
NIP Nifedipine 
PHEN Phenacetin 
TST Testosterone 6β-hydroxylation 
ZAT Zatosetron 
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1 Introduction 
1.1 Background 
 
Bilberry fruit (Vaccinium myrtillus) is traditionally used both as a food and as a 
folk medicine (Sjörs, 1989). As a food, bilberry fruit is eaten fresh, dried or pro-
cessed into jams, pie fillings, liqueurs, wine and may serve as a preservative (Small 
& Catling, 1999, 170- 176). Due to its high phenolic content, bilberry extract is 
extensively used as an ingredient in supplements and natural medicines (Yamamoto 
et al., 2013). Bilberry extract contains several bioactive flavonoids (including fla-
vonols) and phenolic acids, with different bioactivities that may have implications 
for health, such as antioxidative effects (Kahkonen et al., 2001). A few flavonoids 
exert cancer chemopreventive effects and are thus used in cancer chemotherapy 
(Yang et al., 2001; Shih et al., 2000).  
 
In folk medicine, bilberry was used to treat inflammations in mouth and trout, 
mild diarrhea, to improve night vision and to lessen bleeding before surgery (Small 
& Catling, 1999, 172-73). Beliefs of bilberry as a medical crop is partly supported 
by in vitro findings (Biedermann et al., 2013; Master et al., 2012; Triebel et al., 
2012; Basu et al., 2010; Karlsen et al., 2010). However, scientific evidence for that 
is limited (Canter & Ernst, 2004; Conquer et al., 1998). 
 
Potential health benefits of bilberry might be compromised by the presence of 
compounds which can interfere with drug metabolism and detoxification, leading to 
so called food-drug interactions, FDI (Thummel & Wilkinson, 1998). FDI may oc-
cur during intestinal absorption, hepatic metabolism and excretion (Guengerich & 
Shimada, 1998). Partly, FDI occur through induction or inhibition of cytochrome 
P450 (CYP450), which is responsible for the biotransformation of a majority of 
drugs (Guengerich & Shimada, 1998). For example, components from grapefruit 
(Ho et al., 2001), St. Johnś wort (Obach, 2000)and blueberry juice (Hanley et al., 
2013) inhibit the activity of CYP450 and, depending on substrate (drug), may either 
increase or decrease its effect (Moon et al., 2006). It is believed that quercetin, my-
ricetin, rutin (Ho et al., 2001) and isorhamnetin interact with CYP450 (Kimura et 
al., 2010). The nature of these interactions is not yet well documented and very little 
in known how gender affects FDI (Dresser et al., 2000). It is well known that 
CYP450 genes are differentially expressed in males and females (Rasmussen et al., 
2011) and, CYP450 activity is also gender related (Skaanild & Friis, 1999) 
 
Liver microsomes contain the full range of CYP450 and thus, are a useful model 
for in vitro studies of CYP450 activity (Bambal & Clarke, 2010,70). Human micro-
somes have been extensively studied but, due to a limited supply and high costs, 
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animal models are being frequently used (Skaanild, 2006). The porcine (pig/mini-
pig) CYP450 enzyme system and drug metabolism is similar to human, suggesting 
that porcine microsomes can be an attractive model to study food-drug interactions 
(Skaanild, 2006). Data from in vitro studies are often used in early stages of drug 
development, to screen a compound against potential FDI and DDI and, provide 
information for designing possible future clinical studies (Ito et al., 2004). 
 
In the present study, bilberry fruit (Vaccnium myrtillus), five flavonols (quercetin, 
rutin, myricetin isorhamnetin) and three phenolic acids (p-coumaric acid, caffeic 
acid and gallic acid) found in bilberry fruit were investigated for their potential to 
inhibit CYP450 activity in vitro. Both reversible and irreversible inhibitions were 
examined. The present study also evaluated the possibility of gender-related differ-
ences in CYP450 activity.  
1.2 Objective 
 
The overall objective of this study was to evaluate the inhibitory potential of fla-
vonols and phenolic acids from bilberry fruit on porcine CYP450 activity. 
 
Specific aims of the study were: 
(1) To investigate in vitro effect of rutin, myricetin, quercetin, isorhamnetin, p-
coumaric acid, gallic acid and caffeic acid on CYP1A and CYP3A activities 
in porcine liver microsomes.  
(2) To investigate gender-related differences in response of CYP1A and CYP3A 
to these phenolic compounds.   
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2 Literature review 
 
2.1 Content of phenolic compounds bilberry fruit (Vaccinium 
myrtillus) 
 
The content of phenolic compounds in bilberry fruit (V. myrtillus) is mainly rep-
resented by flavonoids and phenolic acids (Häkkinen et al., 1999).  
Flavonoids are characterized by antioxidative-, (Kähkönen et al., 2001; 
Kähkönen & Heinonen, 2003), enzyme inhibition-, chelating- and reduction activi-
ties (Di Carlo et al., 1999).  Many flavonoids are well distributed in most plant 
foods, where they are present in glycosylated forms (Mikulik-Petkovesk, 2012). In 
the human diet, berries have been suggested to be the most concentrated source of 
glycosylated flavonols (Mikulik-Petkovesk, 2012).  Flavonols are one of several 
flavonoid subgroups which, in bilberry fruit are represented e.g. by quercetin and 
myricetin and their glycosylates, isorhamnetin (Mikulik-Petkovesk, 2012) which is 
the 3´-methylated form of quercetin (Breinholt et al., 2002) and, rutin, which is a 
quercetin glycosylate (Moze et al., 2011).  
Phenolic acids exert similar effects to flavonoids, (Hakkinen et al., 1999; Yang 
et al., 2001) and are represented in bilberry fruit e.g. by p-coumaric acid and caffeic 
acid, which are derivates of hydroxycinnamic acid and gallic acid, a derivate of hy-
droxbenzoic acid (Häkkinen et al., 1999). The content and concentration of phenolic 
compounds in bilberry fruit vary, depending on several factors, e.g. geographic lo-
cation (Åkerström et al., 2010) and season (Moze et al., 2011).  
Recent findings suggested that flavonoids such as flavonols may be responsible 
for several health beneficial effects such as, antiallgeric (quercetin), antiatherogenic 
(quercetin), anticancer (quercetin, rutin), antidiabetic (quercetin), antidiarrhoeal 
(quercetin, myricetin), antihepatotoxic (quercetin), anti-inflammatory (quercetin, 
myricetin), antipsasmotic (quercetin) and antiulcer activity (quercetin, rutin) (Di 
Carlo et al., 1999). Flavonoids are generally accepted as health beneficial and thus, 
individual flavonoids as well as flavonoid rich bilberry extract have become attrac-
tive ingredients in dietary supplements, functional foods and herbal medicine, which 
are easily available, e.g. in supermarkets (Yamamoto et al., 2013; Conquer et al., 
1998; Kalogeromitros et al., 2008). In U.S many of these products are accompanied 
with some kind of medical claim (Kalogeromitros et al., 2008). The regulations and 
demands of clinical studies are not as rigorous as for other conventional drugs 
(Dresser et al., 2000). 
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2.2 Food-drug interaction (FDI) 
 
The increased consumption of supplements, herbal medicines and functional 
foods has evoked awareness of food/herb-drug interactions (Hansen & Nilsen, 
2008). Food-drug interactions (FDI) occur when components from the food by some 
means interact with drug metabolism and modify both drug bioavailability and drug 
effect (Guengerich & Shimada, 1998). FDI may take place during intestinal absorp-
tion, hepatic metabolism and excretion (Guengerich & Shimada, 1998). The present 
study focused on hepatic metabolism, as a site of drug biotransformation. Some 
commonly used herbs and fruits can cause serious alterations in human health if 
consumed simultaneously with certain drugs (Conney, 2003). Grapefruit (Ewards et 
al., 1996; Ho et al., 2001; Girennavar et al., 2005), St. John´s wort (Obach et al., 
2000; Hansen & Nilsen, 2008(Hansen & Nilsen, 2008), ginkgo biloba, (von Moltke 
et al., 2004), chicory root (Rasmussen et al., 2012) and blueberry juice (Hanley et 
al., 2012) are foods that have recently been shown to interact with drug metabolism. 
The active components and the mechanisms are though not yet fully understood 
(Thummel & Wilkonson, 1998).  
 
 
2.2.1 Biotransformation of drugs in the liver  
 
Hepatic biotransformation of drugs (activation/deactivation) determines the bio-
availability and thus the effect of the drug (Guengerish & Shimada, 1998). In the 
liver, cytochrome P450 (CYP450) is responsible for a majority of drug biotransfor-
mations (Guengerish & Shimada, 1998). Phenacetin (Bourrié et al., 1996), nifedi-
pine (Anzenbacher et al., 1997), zatosetron (Ring et al., 1994) and testosterone (An-
zenbacher et al., 1997) are a few examples of drugs that are biotransformed in the 
human liver. Usually, biotransformation is divided into two phases, of which phase 
1 includes CYP450 oxidation, resulting in increased solubility (polarity) of the drug 
and provision of sites for conjugation with polar units e.g. glucuronate or sulfate 
(Thummel & Wilkonson, 1989). The following phase II metabolism (conjugation) 
is then carried out by other enzymes to further increase the solubility of the xenobi-
otic and/or endogenous metabolites and facilitate their excretion from the body 
(Preusse & Skaanild, 2011, 148).  
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2.3 Cytochrome P450 
 
Cytochrome P450 (CYP450) is a superfamily of hemoprotein containing mixed 
function monooxygenases, which are responsible for phase I biotransformation of 
drugs and other xenobiotic compounds such as, environmental pollutants and, en-
dogenous substances such as steroids and fatty acids (Conney, 2003). In human, 
approximately 55 isoforms of CYP450 are known, of which only some (belonging 
to CYP450 family 1, 2 and 3) are relevant for drug metabolism (Thummel & Wil-
kinson, 1998).  
 
2.3.1 CYP450 isoform 1A  
 
Cytochrome P450 subfamily 1A (CYP1A) in human, consists of two major 
isoforms, 1A1 and 1A2 (Venkatakrishnan et al., 2001). CYP1A1 is not significantly 
expressed in the human liver, but was found in the intestine and lungs (Venkata-
krishnan et al., 2001). CYP1A2 is the major CYP1 gene family product, present in 
hepatic microsomes (Moon et al., 2005), representing approximately 13% of the 
total amount of CYP450 in the human liver (Bambal & Clarke, 2010, 60).   
CYP1Aś are involved in biotransformation (activation and deactivation) of many 
procarcinogens such as aromatic heterocyclic amines and mycotoxins (Macé et al., 
1997), CYP1A´s are popular targets in research on cancer therapy and prevention 
(Conney, 2003). A high CYP1A1 expression in human is associated with increased 
risk of lung cancer in smokers, probably due to an increased activation of procar-
cinogens from the cigarette smoke (Venkatakrishnan et al., 2001), i.e. polycyclic 
aromatic hydrocarbons (PAH´s) such as benso(a)pyrene (Schwartz et al., 2005). 
Both CYP1A isoforms are involved in the metabolism of the estrogen 17β-estradiol 
(E2) (Takemura et al., 2010). 
 
CYP1A2 metabolizes caffeine, theophylline, imipramine, acetaminophen, car-
cinogenic aromatic and heterocyclic amines (Bambal & Clarke, 2010, 66) and, is 
often subject of studies on cancer chemoprevention (Shih et al., 2000; Conney, 
2003). Cancer chemopreventive agents, e.g. quercetin are found in many plant foods 
(Shih et al., 2000). It has been pointed out that components which acts as chemo-
preventive agents in one experimental setting, may have the opposite (hazardous) 
effect in another setting , thus the cancer chemopreventive regimen should also be 
tailored to the individuals where the pathways of carcinogenesis is well known 
(Conney, 2003).  
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2.3.2 CYP450 family 3A 
 
The cytochrome P450 subfamily 3A (CYP3A) in human consists of three 
isoforms, namely CYP3A3, 3A4 and 3A5 (Thummel & Wilkinson, 1998). CYP3A4 
is the quantitatively most important in human, representing approximately 30% of 
the total amount of CYP450 in human liver (Thummel & Wilkonson, 1998).  
CYP3A3 shares over 98% cDNA homology with CYP3A4 and it is not yet estab-
lished whether 3A3 is an own gene product or an allelic variation of 3A4 and, the 
two isoforms are thus collectively named CYP3A4 (Thummel & Wilkinson, 1998). 
CYP3A5 is only found in 10-30% of the hepatic samples (in levels of 10-30% of 
CYP3A4 levels) and, is structurally distinct from CYP3A4 (Thummel & Wilkinson, 
1998).  
Approximately 50% the oxidative metabolism of drugs in the liver is mediated 
by CYP3A4 (Bambal & Clarke, 2010, 60), representing increased risk for drug in-
teractions (Zuber et al., 2002). CYP3A may also chemically activate or deactivate 
carcinogens in the liver (Dresser, 2000). 
 
2.4 Microsomal in vitro studies of CYP450 
 
2.4.1 Model organisms for in vitro studies of CYP450 activity 
 
One of the first CYP450 being isolated and characterized were CYP1A2 in rat, 
(Zuber et al., 2002). Later it was found that CYP1A2 is conserved throughout spe-
cies, including human (Zuber et al., 2002). However, there are many substrates, 
which are metabolized in humans and rats by different isoforms, which makes rat a 
less suitable model for human studies (Zuber et al., 2002). 
 
Pig is a good model for human CYP1A (Zuber et al., 2002) and CYP3A (Zuber 
et al., 2002; Soucek et al., 2001; Skaanild & Friis, 1999; Monshouer et al., 1998; 
Anzenbacher et al., 1997) and, are often used in preclinical pharmacological and 
toxicological studies, because of its many similarities (both physiological and met-
abolic) with human (Suenderhauf & Parrott, 2013).   
Compared to human liver microsomes, where CYP1A1 isoform is not expressed, 
conflicting data have been published on the presence of CYP1A1 in the pig liver 
(Achour et al., 2011). In many studies, CYP1A1 mRNA was detected in the liver of 
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Meishan and Landrace pig (Kojima & Degawa, 2013; Messina et al., 2011), alt-
hough other reported only the presence of CYP1A2 (Achour et al., 2011).  Activity 
of 7-ethoxyresorufin-O-deethylase (EROD) is commonly used as a probe reaction 
to estimate CYP1A activity. Both the expression of CYP1A and EROD activity dif-
fered between male and female pigs (Skaanild & Friis, 1999). In female pigs, 
CYP1A activity was higher in female compared to male (Rasmussen et al., 2012). 
In pigs, the isoforms CYP3A29 and CYP3A39, representing 14% of total 
CYP450 content, are homologous to human CYP3A4/5 (Anchour et al., 2011). In 
porcine thus, the amount of hepatic CYP3A is less than in human (Table 1).  
 
 
 
 
Table 1. Percentage of the most important drug metabolizing enzymes present in human 
liver relative to their homologues in porcine liver microsomes and amount of drug metabo-
lism in human liver. 
 
Most relevant drug metabolizing CYP450 isoforms 
 3A 1A2 2A6 2B6 2C8 2C9 2C19 2D6 2E1 3A5 
Total, % 
      Human: 
 
341 131 51 31 61 171 0.31 21 151 21 
      Porcine: 142  342  162 262   
Drug metabol-
ism (%)  
      Human: 501 Less1  151 251 Less1 
  
1 Bambal & Clarke, 2010, 60, 2 Achour et al., 2011  
2.4.2 CYP450 regulation  
 
The mechanism of CYP450 regulation is well studied in human (Venkatakrishnan 
et al., 2001); however, less data on porcine CYP450 is available (Preusse & 
Skaanild, 2012) . Regulation of CYP450 expression depends on various factors and 
their combination, including the presence of substrate, genetic background, hormo-
nal status, age, gender etc. (Tsyrlov et al., 1994; Hodek et al., 2002; Rasmussen et 
al., 2011; Zamaratskaia et al., 2005; Brunius et al., 2012; Zamaratskaia et al., 2011 
Zamaratskaia et al., 2012). The mechanisms of this regulation involve orphan nu-
clear receptors, the major transcriptional factor of CYP450 expression regulation 
(Wang & LeCluyse, 2003). Some CYP450 are regulated on a post-transcriptional 
level (Brunius et al., 2012). Additionally, CYP450 activity can be directly regulated 
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by the presence of inhibitors, for example bioactive compounds in the diet (Hodek 
et al., 2007).  
 
Both breed- and gender-related differences in CYP450 activity have been demon-
strated in porcine microsomes (Kojima & Degawa, 2013; Rasmussen et al., 2012; 
Rasmussen et al., 2011; Skaanild & Friis, 1999). Even though the total amount of 
CYP450 did not differ between male and female pigs, the expression and catalytic 
rate of CYP1A-mediated EROD and CYP3A-mediated testosterone 6β-hydroxyla-
tion differed between male and female pigs (Skaanild & Friis, 1999). The activity 
of CYP1A2 was observed to be higher in female compared to male pigs (Skaanild 
& Friis, 1999). The same study also demonstrated that the gene expression and pro-
tein concentration of CYP1A2 were higher in female than in male pigs (Skaanild & 
Friis, 1999).  
 
2.4.3 CYP450 catalytic activity 
 
Most CYP450 isoforms in liver microsomes metabolize a variety of substrates 
and thus participates in different catalytic activities (Guengerich, 1997). The cata-
lytic activities of individual CYP450 isoforms are commonly assessed using probe 
(or marker) substrate(s) (Venkatakrishnan et al., 2001). A probe substrate is a mol-
ecule which is metabolized by one specific isoform and thus, metabolism of a probe 
substrate can be used to estimate activity of a specific isoform (Garcia-Serna & 
Mestres, 2011). Catalytic activities of individual CYP450 enzymes depends on var-
ious factors and vary between individuals (Bourrié et al., 1996), between species 
(Zamaratskaia et al., 2012) and between genders within the same species (Rasmus-
sen et al., 2011). 
 
CYP1A 
In human, CYP1A activity is usually estimated as a rate of ethoxyresorufin O-
deethylation (EROD) (Anzenbacher et al., 1997; Guengerich, 1997). EROD activity 
was detected in the microsomes from minipig, although obtained values were some-
what lower than in the microsomes from human (Anzenbacher et al., 1997). EROD 
activity was also detected in conventional pigs, however, it was suggested that 
EROD might not accurately reflect CYP1A1 activity, as it is probably metabolized 
by two isoforms (Zamaratskaia et al., 2011; Zamaratskaia & Zlabek, 2009). Porcine 
CYP1A activity may also be estimated as a rate of methoxyresorufin O-demethyla-
tion (MROD) (Zamaratskaia & Zlabek, 2009). Phenacetin is metabolized to parace-
tamol (a mild analgestic) in humans and is a typical probe substrate for human 
CYP1A (Bourrié et al., 1996). The catalytic activities of CYP1A-mediated EROD, 
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MROD and phenacetin O-deethylation in human and porcine, is illustrated in Table 
2.  
 
 
Table 2. The catalytic activities of CYP1A in human (H) and porcine (P) micro-
somes are estimated using different common substrates. Results are presented in 
units used in the original references. 
Microsomal CYP1A  
Substrate Reaction Specie Catalytic activity  
 
Ethoxyresorufin O- deethylation H 190 pmol/min/nmol 1 
 O- deethylation P 27.3 pmol/min/nmol 1 
 O- deethylation H 851 pmol/min/mg 2 
 O-deethylation H 70 pmol/min/mg 4 
 O-deethylation H 300 pmol/min/mg 4 
Mehthoxyresorufin O-demethylation P 0.8 pmol/min/mg 3 
Phenacetin O-deethylation H 6800 pmol/min/mg 4 
1Anzenbacher et al., 1997,  2Zlabek & Zamaratzkaia, 2012, 3Zamaratskaia & Zlabek, 2009, 4Bourrié 
et al., 1996 
 
 
CYP3A 
BFC (7-benzyloxy-4-trifluoromethylcoumarin) O-debenzylation to HFC (7-hy-
droxy-4-triflouromethylcoumarin) is mediated by CYP3A in both human (Hansen 
& Nilsen, 2008) and porcine microsomes (Tomankova et al., 2012; Zamaratskaia et 
al., 2012). In pigs, BFC is used as a probe substrate for CYP3A activity (Zamarats-
kaia et al., 2012; Tomankova et al., 2012). However, it is still not known if 
CYP3A29 and CYP3A39 are the main isoforms mediating BFC metabolism. In 
pigs, CYP3A differed between Landrace and Duroc pigs (Zamaratskaia et al., 
2012). Zatosetron (Ring et al., 1994) and nifedipine (Anzenbacher et al., 1997) are 
both metabolized by CYP3A in human.  The catalytic rate at which nifedipine is 
metabolized in human is almost identical to minipig (Anzenbacher et al., 1997). 
Testosterone 6β-hydroxylation is catalyzed in human and porcine microsomes by 
CYP3A in a similar manner, suggesting that testosterone can be used as a probe 
substrate to estimate both human and porcine CYP3A activity (Anzenbacher et al., 
1997). Catalytic rates of CYP3A-mediated BFC, nifedipine, zatosetrone and testos-
terone metabolism in human and porcine, is presented in Table 3. 
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Table 3. Common substrates to estimate microsomal CYP3A catalytic activities are esti-
mated using common substrates, such as BFC (7-benzyloxy-4-trifluoromethylcouarin), 
nifedipine, zatosetron and testosterone, in human (H) and porcine (P) microsomes.  Re-
sults are presented in units used in the original references. 
       P-Lan= porcine landrace,  P-Dur= porcine Duroc=, P-cross= porcine cross-breed, Pmini= porcine mini-
pig.  
 
Microsomal CYP3A   
Substrate 
  
Reaction 
 
Species 
  
Catalytic activity 
   
BFC O-debenzylation P-cross  35.1 pmol/min/mg product1 
 O-debenzylation P-Lan  334 pmol/min/mg2 
 O-debenzylation P-Dur  275 pmol/min/mg2 
Nifedipine Oxidation H  2205 pmol/product/min/nmol3 
 Oxidation Pmini  2193 pmol/product/min/nmol3  
Zatosetron N-oxidation H  1790 pmol product/min/mg protein4 
Testosterone 6β-hydroxylation H  1340 pmol/product/min/nmol3 
 6β-hydroxylation P  1330 pmol/product/min/nmol3 
1Tomankova et al., 2012, 2Zamaratskaia et al., 2012, 3Anzenbacher et al., 1997, 4 Ring et al., 1994 
2.5 Inhibition of CYP450  
 
There are several mechanisms of inhibition and, some inhibitors may demonstrate 
more than one type of inhibition (Thummel & Wilkinson, 1998). Generally, in vitro 
studies, of CYP450 are carried out using a probe substrate to measure and quantify 
the inhibition over a range of substrate and inhibitor concentrations (Thummel & 
Wilkonson, 1998). Most CYP450 follow Michaelis-Menten kinetics, showing a hy-
perbolic curve when the initial velocity, V0 is studied as a function of product for-
mation (Berg et al., 2007, 216-228; Thummel & Wilkinson, 1998). To investigate 
the reversibility of inhibition, a pre-incubation of microsomes with inhibitor before 
addition of a probe substrate is usually used (Thummell & Wilkinson, 1998). An 
increase of inhibition degree after inclusion of a pre-incubation step, suggests irre-
versibility, meaning that the enzyme-substrate complex does not dissociate, whereas 
the degree of reversible inhibition is not affected by pre-incubation and then, the 
enzyme and substrate complex dissociates rapidly (Thummel & Wilkinson, 1998). 
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Due to a huge number of reactions catalyzed by CYP1A and CYP3A, inhibition 
of these isoforms by dietary components may result in alterations in essential phys-
iological processes (Bushra et al., 2011). This underlines the importance of dietary 
components and hepatic metabolism (Bushra et al., 2011). 
 
2.5.1 Irreversible inhibition 
 
Irreversible inhibition is also called mechanism based or suicide inactivation, and 
causes permanent reduction in enzyme activity (Thummel & Wilkinson, 1998). The 
concentration of the inhibitor, needed to decrease the activity of the enzyme by 50% 
(IC50) is used as a characteristic measure, enabling comparisons between different 
inhibitors (Thummel & Wilkinson, 1998). 
 
Examples of irreversible inhibitors found in food is e.g. the grapefruit constituent 
6´,7´-dihydroxybergamottin (furanocoumarin) which markedly inhibits metabolism 
of CYP3A substrates, both in vitro and in vivo (Edwards et al., 1996; Thummel & 
Wilkinson, 1998). Grapefruit juice itself which is a well-known irreversible inhibi-
tor of CYP3A activity (Seden et al. 2010; Hanley et al., 2012). Several steroids also 
inhibited (inactivated) CYP3A activity in human, irreversibly (Thummel & Wil-
kinson, 1998) and in pig (Rasmussen et al., 2011; Zamaratskaia et al., 2012). 
 
2.5.2 Reversible inhibition 
 
If the degree of inhibition is unaffected by inclusion of a pre-incubation step, then 
the inhibition is considered to be reversible and the mode (mechanism) of inhibition 
may be further determined (competitive-, uncompetitive-, noncompetitive or mixed) 
using several substrate concentrations (Thummel & Wilkinson, 1998).  
Competitive inhibitors have a higher affinity to the enzyme than to the enzyme-
substrate complex and, as more substrate is added, the inhibition will be overcome, 
why these inhibitors will be recognized by increased KM (substrate concentration 
that yield a half-maximal velocity) and unchanged Vmax (maximum velocity) (Berg 
et al., 2007, 216-228).  
Non-competitive inhibitors can bind to the enzyme simultaneously as the enzyme 
as the substrate, but at different sites, and are being recognized by a decreased Vmax 
and unchanged KM (Berg et al., 2007, 216-228). 
Uncompetitive inhibitors have higher affinity to the enzyme-substrate complex 
than to the enzyme (Berg et al., 2007, 216-228). Some typical chemical inhibitors 
of CYP1A and CYP3A are listed in Table 4. 
The inhibition constant is also called dissociation constant (Ki) and is the binding 
affinity of the reversible inhibitor, indicating the potency of the inhibitor (Berg et 
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al., 2007, 226). The most potent reversible inhibitors have Ki-values under 1µM 
(Thummel & Wilkinson, 1998). Examples of potent reversible inhibitors include 
azole antifungal agents (e.g. ketoconazole) and HIV protease inhibitors (Thummel 
& Wilkinson, 1998). Reversible inhibition by blueberry juice (BBJ) was recently 
demonstrated, which inhibited CYP3A triazolam- (sedative-hypnotics) and buspi-
rone (anti-anxiety medicine) metabolism in human liver microsomes in vitro (Han-
ley et al., 2012). Pre-incubation did not substantially enhance the degree of inhibi-
tion, indicating a reversible mode of inhibition (Hanley et al., 2012). The same blue-
berry juice, in a human intervention, changed the metabolic pattern of major drug 
metabolizing enzymes (CYP450) in the liver (Hanley et al., 2012). The active com-
ponents in the blueberry juice were never examined (Hanley et al., 2012).  
The concentration of the inhibitor [I] relative to its inhibition constant in vitro Ki, 
that is [I]/Ki ratio is used to estimate the degree of inhibition (Thummel & Wilkins, 
1998; Ito et al., 2002). Ki values above 75-100µM is usually not physiologically 
relevant inhibitors (Thummel & Wilkinson, 1998). 
 
 
 Table 4. Chemical in vitro inhibitors of CYP1A and 3A in human (H), porcine 
(P) and mice (M). --- indicates no inhibition. 
       aNF =a-napthoflavone, FUR =furafylline, KET =ketoconazole, 7βest =7β-estradiol, TAO =triacety-
loleandomycin, DBM =6´,7´-dihydroxybergamottin, PHE =phenacetin, EROD =7-ethoxyresorufin O- 
deethylation, BROD =7-benzyloxresorufin, BFC =7-benzyloxy-4-trifluorometylcoumarin, MID =midazo-
lam 1´-hydroxylation, NIF= nifedipine oxidation, TST =testosterone 6β-hydroxylation 
CYP450  
Inhibi-
tor Reaction 
Specie 
/Sex 
IC50 
(µM) 
Ki 
(µM) Mechanism 
1A aNF PHE5 H  0.0135 Competitive5 
 FUR PHE1 H 4,71  competitive1 
 KET PHE1 H ~31  competitive1 
  EROD3 P --- --- ---3 
  BROD3 P/male  10.43 non-competitive3 
  BROD3 P/female  14.23 non-competitive3 
3A  BFC4 P   non-competitive4 
  BFC8 H 0.18   
  MID6 H  14.96 non-competitive6 
 7βest BFC4 P   irreversible4 
 TAO NIF7 H   inhibition 7 
  NIF7 P   inhibition7 
 DBM TST2 M 252  Irreversible2 
1Bourrié et al., 1996, 2Edwards et al., 1996, 3Zlabek & Zamaratzkaia, 2012, 4Zamaratskaia et al., 2012, 5von 
Moltke et al., 1996, 6Gibbs et al., 1999, 7Anzenbacher et al., 1997 
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2.6 CYP450 inhibition by flavonoids 
 
In general, flavonoids are inter alia characterized as potential enzyme inhibitors 
and, due to their wide distribution in plant food their role as potential CYP450 in-
hibitors makes them important for evaluating FDI (Di Carlo et al., 1999). Several 
reports have demonstrated that a variety of flavonoids may interact with CYP450-
mediated drug metabolism, by inhibiting CYP450 activity in the liver of humans 
and animals (Tsyrlov et al., 1994; Obach et al., 2000; von Moltke et al., 2012; 
Chaudhary & Willett, 2006; Kimura et al., 2010; Ring et al., 1994; Ho et al., 2001; 
Obach et al., 2000; von Moltke et al., 2012). 
The bioactivity of several flavonols might include interactions with CYP450 
(Bushra et al., 2011). Thus, a simultaneous intake of drugs and flavonols may result 
in food-drug interactions such as inhibition (Breinholt et al., 2002).  
The structure of flavonols is a crucial factor for determining its effect on CYP450 
activity (Ho & Saville, 2001). The strength of inhibition of CYP450 by flavonols 
differs depending on number and location of hydroxyl groups of the flavonol skel-
eton (Breinholt et al., 2002). In liver microsomes, flavonols, such as kaempferol is 
3´-hydroxylated and tamarixetin is 4´-demethylated to quercetin (Breinholt et al., 
2002). This metabolism was strongly inhibited by the CYP1A inhibitor (and drug) 
fluvoxamine (kaempferol: IC50=1.2µM and tamarixetin: IC50=1.4µM), suggesting 
that flavonoids and drugs are metabolized by the same CYP450 enzymes (Breinholt 
et al., 2002).   
The location as well as the number of hydroxyl groups on the flavonoid skeleton 
may play a crucial role for the CYP450 inhibition potency of specific flavonols (Ho 
et al., 2001).  
 
 
2.6.1 CYP1A inhibitors 
 
Quercetin was shown to inhibit CYP1A activities estimated as EROD and MROD 
activity in human microsomes (Tsyrlov et al., 1994). In the same human micro-
somes, the potency of quercetin to inhibit MROD (IC50=0.4µM) was high com-
pared to EROD (IC50=4.1µM) (Tsyrlov et al., 1994). In mice microsomes, the same 
inhibition pattern was observed, indicating that the potencies of quercetin to inhibit 
EROD and MROD are comparable between human and mice microsomal CYP1A 
(Tsyrlov et al., 1994). As a component of St. John´s wort, quercetin inhibited EROD 
activity in supersomal human recombinant CYP1A with Ki =0.2µM and IC50= 
6.0µM (Chaudhary & Willett, 2006). Kinetic studies, using phenacetin as a sub-
strate, demonstrated that PHE was non-competitively inhibited (Ki =3.3µM, IC50= 
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<10µM) by 10 µM quercetin, in recombinant, microsomal CYP1A (Obach, 2000). 
As a component found in Ginkgo biloba, quercetin was studied in hepatic micro-
somes, donated from two humans and, phenacetin to paracetamol was inhibited, 
with IC50=3.0µM (Moltke et al. (2012). Summary of CYP1A inhibitors are pre-
sented in Table 5.  
 
 
Table 5. CYP1A inhibition by flavonols. Summary of studies presenting in vitro inhibition 
of human c-DNA derived CYP1A (H/cDNA) activity, in human microsomal CYP1A 
(H/mcs), in human recombinant CYP1A (H/r-mcs) and mice (M) by flavonols.  
       EROD =7-ethoxyresorufin O- deethylation, MROD= methoxyresorufin O-deethylation, PHE= phenacetin O- 
deethylation, inhib= inhibition, n.i.= indicates no inhibition, a.u.= arbitrary units 
CYP1A  
Inhibitor Organism/ 
enzyme 
source 
Sub-
strate 
Kinetic  
Flavonol 
 
Conc. IC50 
(µM) 
Ki 
(µM) 
Mode of  
inhibition 
Quercetin 0-25µM1 H/c-DNA1 EROD1 41.11  inhib1 
 0-25µM1 M/c-DNA1 EROD1 20.31  inhib1 
 0-25µM1 H/c-DNA1 MROD1 0.41  inhib1 
 0-25µM1 M/c-DNA1 MROD1 29.11  inhib1 
 a.u. H/r-mcs2 PHE2 <102 3.32 non-competitive2 
 <10µg/ml
3 H/mcs3 PHE3 3.03  inhib3 
 0.1-10µM4 H/r-mcs4 EROD4 6.04 0.254 inhib4 
Myricetin 0.1-10µM4 H/r-mcs4 EROD4 344 1.44 inhib4 
Rutin 0.1-10µM4 H/r-mcs4 EROD4 N.I.4 N.I.4 n.i.4 
1 Tsyrlov et al., 1994, 2Obach et al., 2000, 3 von Moltke et al., 2012,  4Chaudhary & Willett, 2006 
 
 
 
Myricetin inhibited EROD activity in supersomal recombinant human CYP1A, 
with Ki=1.4µM and IC50=34µM (Chaudhary & Willett, 2006). 
The potency of isorhamnetin to inhibit CYP1A2 was strongly reduced by steric 
collisions in its way, suggesting that isorhamnetin not fit well into the hydrophobic 
pocket (active site) of CYP1A2 (Takemura et al., 2010). For strong CYP1 inhibition 
to occur flavonoids require a 2-3 double bonds on the C-ring (Takemura et al., 
2010). 
Rutin (10µM) did not inhibit CYP1A1 in human microsomes (Chaudhary & Wil-
lett, 2006). 
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2.6.2 CYP3A inhibitors  
 
Quercetin inhibited CYP3A-mediated triazolam hydroxylation (Moltke et al., 
2010), zatosetron N-oxidation (Ring et al., 2004) and quinine 3-hydroxylation (Ho 
et al., 2001) in human microsomes. Quercetin from grapefruit, inhibited 55-60% 
(30-45% activity remaining) of CYP3A-mediated quinine 3-hydroxylation, in two 
human donors, with IC50 values of 82µM and 41µM (Ho et al., 2001). The potency 
of quercetin to inhibit CYP3A-mediated triazolam hydroxylation (IC50=4.1µM) 
(von Moltke et al., 2010) was higher than its potency to inhibit CYP3A-mediated 
zatosetron oxidation (Ki=13.6µM) (Ring et al., 2004). The inhibition mode of 
CYP3A-mediated zatosetron oxidation, by quercetin was uncompetitive (Ring et 
al., 2004). Quercetin inhibited human recombinant CYP3A testosterone 6β-hydrox-
ylation, (IC50= 22.1µM) (Kimura et al., 2010) more potently than CYP3A phenac-
etin O-deethylation, IC50=82µM (Obach et al., 2000). 
Myricetin (aglycon) inhibited CYP3A-mediated triazolam hydroxylation, with an 
IC50 value of 6.4 µM (von Moltke et al., 2012). When different concentrations (10-
200 µM) of myricetin was studied, 78-94% of CYP3A quinine 3-hydroxylation (22-
6% remaining) was inhibited, which was more than by quercetin but, the IC50 value 
could not be calculated (Ho & Saville, 2001). Kinetic studies of CYP3A-mediated 
testosterone hydroxylation demonstrated approximately 70% irreversible inhibition 
(~30% activity remaining) by myricetin, with a Ki value of 44.5µM (Kimura et al., 
2010).   
Isorhamnetin inhibited testosterone hydroxylation (≥80% inhibition and ≥20% 
remaining) more than myricetin and less than quercetin (Kimura et al., 2010)  
CYP3A-mediated quinine 3-hydroxylation was not inhibited by rutin at low and 
medium concentrations but, a modest inhibition was observed at high concentrations 
(Ho & Saville, 2010) and, no significant inhibition of CYP3A-mediated testosterone 
hydroxylation was observed (Kimura et al., 2010). A summary of CYP3A inhibitors 
is presented in Table 6. 
 
The potency of flavonols to inhibit CYP3A quinine 3-hydroxylation increased by 
increased number of hydroxyl substituents on the flavonol seleton (Ho et al., 2001).  
Myricetin, with 6 OH-groups was found to be the most potent inhibitor of CYP3A 
quinine 3-hydroxylation, while quercetin with 5 hydroxyl groups was the second 
most potent and, rutin with 4 hydroxyl groups was found to have least potency (Ho 
et al., 2001). Presence of hydroxyl groups at the R4 position on the B ring (as quer-
cetin have), specifically enhanced the inhibition potency (Ho et al., 2001). 
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It should be emphasized that the concentrations of flavonoids tested in in vitro 
studies were likely higher than typical bioavailable concentrations in humans. Thus, 
the results should be interpreted with caution.  
 
 
 
Table 6. CYP3A inhibition by flavonols. Summary of studies presenting in vitro inhibition of 
human microsomal CYP3A (H/mcs) and in human recombinant CYP3A (H/r-mcs) by flavo-
nols. 
       ZAT =zatosetron N-oxidation, QUI =quinine 3-hydroxylation, TRI =triazolamhydroxylation, TST= testosterone 
6β-hydroxylase, n.d. =not detected 
 
CYP3A   
Inhibitor Organism/ 
enzyme 
source 
Sub-
strate 
 
Kinetic  
Flavonol Conc. 
 
Ki 
µM 
IC50 
µM 
Inhibition (mode) 
Quercetin 12.5-100µM2 H/mcs2 ZAT2 13.62  Uncompetitive2 
 10-200µM3 H/mcs3 QUI3  413 Inhib.3 
 10-200µM3 H/mcs3 QUI3  823 Inhib.3 
 9.9µM5 H/mcs5 TRI5  4.15 Inhib.5 
 100µM1 H/r-mcs1 TST1  22.11 Inhib.1 
Myricetin 10-200µM3 H/mcs3 QUI3  n.d. Inhib.3 
 9.9µM5 H/mcs5 TRI5  6.45 Inhib.5 
 100µM1 H/r-mcs1 TST1 44.51  Inhib.1 
Isorhamnetin 100µM1 H/r-mcs1 TST1 16.61  Inhib.1 
Rutin  100µM1 H/r-mcs1 TST1 -  - No inhib.1 
 10-200µM3 H/mcs3 QUI3 - - No-modest inhib.3 
1 Kimura et al., 2010, 2 Ring et al., 1994, 3Ho et al., 2001, 4, 5 von Moltke et al., 2012  
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3 Material & Method 
3.1 Chemicals 
 
Nicotinamide adenine dinucleotide phosphate reduced form (NADPH), 7-ben-
zyloxy-4-triflouromethylcoumarin (BFC; CYP3A substrate), 7-hydroxy-4-tri-
flouromethylcoumarin (HFC; product of BFC metabolism), 7-ethoxyresorufin 
(CYP1A substrate), resorufin (product of 7-ethoxyresorufin metabolism), rutin, my-
ricetin, quercitin, isohamnetin, p-coumaric acid, gallic acid and caffeic acid (inhib-
itors) were obtained from Sigma-Aldrich (Steinheim, Germany). Methanol and ac-
etonitrile of HPLC grade were obtained from Merk (Darmstadt, Germany).  
3.2 Study design 
 
The flowchart in Figure 1 illustrates the design of the experimental process. First, 
bilberry compounds (one concentration per compound) were evaluated for their 
ability to inhibit CYP3A and CYP1A activity. If the activities were inhibited by at 
least 21%, the reversibility of the inhibition was evaluated by the including of a pre-
incubation step. Reversible inhibitors were further analyzed for the inhibition mode 
using multiply substrate concentrations. The details of analysis, substrate and inhib-
itor concentrations are described in sections 3.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CYP450 
No inhibition Inhibition 
Reversible Irreversible 
Competitive Non-competitive 
Figure 1. The flow illustrates the design of the experimental process. 
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3.3 Biochemical analysis  
 
3.3.1 Bilberry extract preparation 
 
The powder of dried bilberry fruits (0.5 mg) was extracted by overnight incuba-
tion, at 35°C in 50% methanol and 1-2 M HCl (Häkkinen et al. 1998). The mixture 
then was evaporated to dryness, re-dissolved in 1.5 ml of 100% methanol and fil-
tered before use. Extract was further diluted with 100% methanol to obtain 6 work-
ing solutions in a 2000, 200, 20, 8 and 2 dilution of undiluted extract. Working 
solutions were stored at -80°C. A number of working solution indicates dilution 
factor from the undiluted extract (undiluted bilberry extract -1, extract diluted 2000 
times -2000). 
3.3.2 Microsomal preparation 
 
The calcium aggregation method was used for microsomal preparation. Briefly, 
2 g liver tissue was homogenized in Tris-EDTA buffer (50 mM Tris-HCl, 150mM 
Potassium chloride, 2 mM EDTA, pH 7.4). The obtained homogenate was diluted 
with Tris-EDTA buffer containing 8 mM CaCl2, incubated for 4 minutes and cen-
trifuged at 25.000 x g for 30 minutes at 4⁰ C (Rasmussen et al., 2011). All steps 
were carried out on ice. The microsomal protein concentration was measured with 
a commercially available kit (Bio-Rad Laboratories Inc., Hercules, CA, USA) ac-
cording to the manufacturer´s instructions. Microsomes were diluted to a final pro-
tein concentration of 10 mg/ml and stored at -80⁰ C until used. 
 
 
3.3.3 Cytochrome P450 enzymatic assays 
 
 
CYP1A activity. A stock solution in resorufin was prepared in 100% methanol. 
Standard curves were constructed using resorufin in a concentration range from 0.05 
to 5 pmol/ ml in the mixture of 50 mM potassium phosphate buffer, pH 7.4:methanol 
(1:1) in duplicate. CYP1A activity was assessed by incubating 0.20 mg/ml of mi-
crosomal proteins with NADPH at a concentration of 0.5 mM and the substrate, 7-
ethoxyreorufin at a concentration of 2 µM. After 5 minutes incubation in a water-
bath at 37⁰ C, the reaction was terminated by 500 µl of ice-cold methanol, followed 
by centrifugation at 7500 x g for 10 minutes. The supernatants were analyzed with 
HPLC. HPLC conditions used were: isocratic mobile phase: 20 mM phosphate 
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buffer pH 6.8:methanol:acetonitrile (52:45:3), flowrate: 1.0 ml/minute, fluores-
cence detector of 560 and 586 nm (excitation and emission), injection volume: 10µl 
and run time 3 minutes. CYP1A activity is reported as picomoles of resorufin 
formed per minute per milligram of microsomal protein. 
 
CYP3A activity. A stock solution HFC was prepared in 100 % methanol. Known 
amounts of HFC in a range of 2 to 2000 pmol/ml were added to the mixture of 50 
mM potassium phosphate buffer, pH 7.4:methanol (1:1) in duplicate. CYP3A activ-
ity was assessed by incubating 0.25 mg/ml of microsomal proteins with NADPH at 
a concentration of 0.5 mM and the substrate, BFC at a concentration of 100µM. 
After 10 minutes of incubation in a water bath at 37⁰ C, the reaction was terminated 
by 500 µl of ice-cold methanol. The resulting mixtures were centrifuged at 7500 x 
g for 10 minutes and the supernatants were analyzed with HPLC. HPLC conditions 
used were: isocratic mobile phase: 20 mM phosphate buffer pH 6.8: methanol: ace-
tonitrile (52:45:3), flowrate: 0.6 mL/min, fluorescence detection at 410 and 538 nm 
(excitation and emission), injection volume: 10 µl and run time 8 min. CYP3A ac-
tivity is reported as picomoles of HFC formed per minute per milligram of micro-
somal protein. 
In both assays, a Hypersil ODS column (3µm, 60 x 4.6 mm Hewlett-Packard) 
equipped with a guard column was used. 
 Inhibition studies were performed using two pools of microsomes from three 
male pigs in each and, two pools of microsomes from two female pigs in each. 
An overview of the assay conditions is presented in Table 7. 
 
Table 7. Assay conditions for CYP1A and CYP3A. 
Substrate 
Iso-
form 
Microsomal 
protein 
amount  
Incuba-
tion  
Substrate 
conc. NADPH 
Ethoxyresoru-
fin 
1A 0.20 mg/ml 5 min 2 µM 0.5 mM 
BFC 3A 0.25 mg/ml 10 min 100µM 0.5 mM 
 
 
3.3.4 Bilberry extract 
 
Various concentrations of methanol bilberry extract were incubated with micro-
somes, NADPH and a specific probe substrate (either BFC for CYP3A or 7-ethox-
yresorufin for CYP1A). Serial dilutions were prepared by addition of methanol to 
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yield six concentrations of bilberry extract and, the extract concentrations were re-
ported in arbitrary units indicating the dilution of a stock extract (0.5 mg of bilberry 
powder in 1 ml of methanol). The incubation was allowed to proceed as above de-
scribed in enzymatic assays. 
 
3.3.5 Individual compounds from bilberry extract 
 
Inhibition of CYP3A and CYP1A activities by following compounds typically 
found in bilberries: rutin, myricetin, quercetin, isorhamnetin, p-coumaric acid, gallic 
acid and caffeic acid. First, bilberry compounds (one concentration per compound) 
were screened for their ability to inhibit CYP3A and CYP1A activity in vitro. Solu-
tions were added to eppendorf tubes in the following order and quantity:  inhibitor 
(16 µM in final incubation volume), freshly pre-mixed incubation buffer, substrate 
and NADPH; the reaction was initiated by addition of microsomal protein. The final 
concentration of methanol was 0.1% in the incubation volumes. The same amount 
of methanol was added to the control incubations. Percentage of inhibition calcula-
tions were based on differences between the control incubations (without inhibitor, 
100%) and the incubations in the presence of inhibitor. A control activity without 
addition of inhibitor was assessed within each assay. The activity was regarded as 
inhibited if it differed from the control activity by at least 21%. 
3.3.6 Enzyme inhibition kinetics 
 
The compounds, showing ability to inhibit either CYP3A or CYP1A, were further 
tested using 3 concentrations (16, 32 and 128 µM). The incubations were performed 
with and without inclusion of pre-incubation step (5 min before addition of sub-
strate) in order to assess reversibility of inhibition. If inhibition degree increased 
after inclusion of a pre-incubation step, the inhibition was considered as irreversible 
and 50% inhibition of enzyme activity (IC50 value) was determined. If inhibition 
degree was not affected by inclusion of pre-incubation step, the inhibition was con-
sidered as reversible and mode of inhibition was further determined by kinetic anal-
ysis using several substrate concentrations. CYP3A activity was determined at BFC 
concentrations from 0.1 to 150 µM and CYP1A activity was determined at 7-ethox-
yresorufin concentrations from 0.1 to 4 µM. 
The incubations were processed as described in enzymatic assays section. All 
measurements were performed in duplicate. 
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3.4 Statistical analysis 
 
The inhibition mode (competitive and non-competitive) and inhibition constants 
(Ki) were determined with GraphPad Prism version 4.0 for Windows, GraphPad 
Software (San Diego, California, USA). The choice of the best-fit enzyme model 
was based on F-test.  
Enzyme activities were considered as altered when inhibition degree exceeded 
20%. No further statistical analysis (p-values) were performed to avoid false posi-
tive results due to low intra-assay variations. 
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4 Results 
4.1 CYP450 activity in the presence of bilberry 
 
Inhibition by bilberry extract on CYP450 activity 
The undiluted bilberry extract (Figure 2) markedly modified the activity of the 
CYP450 isoform 1A in male (remaining activity varied from 61.2 to 64.9%) but not 
in female pigs. The dilution of the extract eliminated this inhibition. The activity of 
CYP3A increased in male and decreased in female pigs in the presence of bilberry 
extract.  
 
Reversibility of inhibition 
Out of the selected compounds (rutin, myricetin, quercetin, isorhamnetin, p-cou-
maric acid, gallic acid and caffeic acid, only myricetin, quercetin and isorhamnetin 
showed potential to inhibit CYP450 activity by at least 21% (remaining CYP450 
activity below 79%)(Figure 3). 
Myricetin and isorhmnetin reversibly inhibited CYP1A- and CYP3A-activity 
(degree of inhibition was not affected by inclusion of pre-incubation step) in the 
microsomes from both male and female pigs (Figure 4). Inhibition of CYP1A by 
quercetin exhibited gender-specific pattern being reversible in the microsomes from 
male, and irreversible in the microsomes from female pigs.  
 
Inhibition mode and Ki values 
CYP1A activity was competitively inhibited by myricetin and isorhamnetin in 
both male and female pigs. Both inhibitors expressed higher potential to alter 
CYP1A activity in female pigs as indicated by lower Ki values. Quercetin compet-
itively inhibited CYP1A activity in male pigs, while in female pigs quercetin acted 
as an irreversible inhibitor, with an IC50 value of 1.3 µM (Figure 5). 
 
Myricetin non-competitively inhibited CYP3A activity in the microsomes from 
male but not female pigs. Isorhamnetin competitively inhibited CYP3A in both male 
and female microsomes, although Ki value was somewhat lower in male compared 
to female pigs (71.2 vs. 93.7 µM, respectively) (Figure 6). 
The results from kinetic measurements are summarized in Table 8. 
28 
 
 A   B 
 
 
 A   B 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Inhibition by bilberry extract, diluted (arbitrary units), with the most dilute. A) 
CYP1A activity and B) CYP3A activity, in the presence of bilberry extract. 
Figure 3. Inhibition by individual bilberry components: A) CYP1A activity and, B) 
CYP3A activity and, only myricetin, quercetin and isorhamnetin showed potential to in-
hibit CYP450 activity by at least 21%. 
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Figure 4. Reversibility, A) CYP1A in the presence of myricetin, isorhamnetin and quercetin 
and B) CYP3A in the presence of myricetin and isorhamnetin  
 
Figure 5. CYP1A saturation curve, EROD.  
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Tabel 8. Mechanism of inhibition of specific CYP450 isoforms by myricetin, 
isorhamnetin and quercetin in porcine liver microsomes.  
CYP 
Individual phe-
nolic compound  
Sex 
(pigs) 
Ki 
(µM) 
IC50 
(µM) 
Mode of inhibition 
1A Quercetin M 0.2  Competitive 
  F  1.3 Irreversible 
 Myricetin M 2.5  Competitive 
  F 4.6  Competitive 
 Isorhamnetin M 99.9  Competitive 
  F 10.8  Competitive 
3A Myricetin M 112.7  Non-competitive 
  F   No inhibition 
 Isorhamnetin M 71.2  Competitive 
  F 93.7  Competitive 
M=male, F=female 
Figure 6. CYP3A (BFC) saturation curve.  
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5  
Discussion  
 
CYP450 is involved in the metabolism of various endogenous and xenobiotic 
compounds; thus, inhibition of individual isoforms by dietary components may have 
undesirable and even harmful effects on essential physiological processes. Addi-
tionally, such inhibition might alter metabolism of drugs. Thus, the effect of food 
components on CYP450 might be carefully studied. 
 
Previous studies demonstrated that several dietary phenolic compounds, such as 
quercetin, myricetin and isorhamnetin have potencies to inhibit activities of some 
CYP450 isoforms in human, rat and mice at concentrations in the range 8-200µM.  
The concentrations of the inhibitors in the present study (16 µM or 8 µM in the 
incubation volume of 500 µl) corresponded to the concentration of quercetin meas-
ured in the liver of pig fed a single quercetin dose (25 mg/kg) (Bieger et al., 2008). 
In the kinetic analysis, higher inhibitor concentrations were also included (32 and 
128 µM) to increase the accuracy in Ki estimation. 
The present study was designed to elucidate potential inhibition of CYP1A and 
CYP3A by several phenolic compounds, in porcine hepatic microsomes. Hepatic 
microsomes from male and female pigs were used in the study. It was recently sug-
gested that interactions between CYP450 and xenobiotic compounds may differ be-
tween male and female (Rasmussen et al., 2011). Moreover, in vitro CYP3E activ-
ities were inhibited by 17βoestradiol in the microsomes from male but not from 
female pigs (Zamaratskaia et al., 2007; Rasmussen et al., 2011). 
 
The present results provide further evidence on gender-related regulation of 
CYP450. First, bilberry extract affected CYP1A and CYP3A activities different in 
male and female pigs. CYP1A activity was lower in the presence of bilberry extract 
only in male and, CYP3A only in female pigs. Further analysis using individual 
component confirmed gender-related differences.  
Quercetin was a potent competitive inhibitor of CYP1A in male pigs and, irre-
versible inhibitor in female pigs. The gender-related pattern of CYP1A inhibition 
by quercetin might explain overall inhibition of male CYP1A by bilberry extract. 
Human CYP1A measured as EROD activity was also inhibited by quercetin (Tsyr-
lov et al., 1994) even though the inhibition was more potent in porcine than in hu-
man.  
Isorhamnetin and myricetin inhibited CYP1A in the microsomes of both male 
and female pigs. Present findings are in line with those on recombinant CYP1B1 
and CYP1A1 (Chaudhary & Willet, 2006), in which myricetin and quercetin were 
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identified as inhibitors of EROD. Chaudhary & Willet (2006) did not, however, 
evaluate the mode of inhibition. 
Quercetin is a well-known inhibitor of human CYP3A. The CYP3A-mediated 
biotransformation of many drugs, i.e. zatosetron (Ring et al., 1994), quinidine (Ho 
et al., 2001), triazolam and testosterone (Kimura et al., 2010; von Moltke et al., 
2004; Obach, 2000) were inhibited by quercetin in humans. The known in vivo in-
teraction between grapefruit juice and the drug nifedipine, in humans is believed to 
be at least partly due to the presence of quercetin in grapefruit juice (Ho et al., 2001). 
Interestingly, CYP3A-mediated BFC metabolism was not inhibited by quercetin in 
pig. This implies specie-related differences in food/feed-drug interactions. More 
studies are needed to investigate the effect of quercetin on porcine CYP3A activity. 
In such studies, several substrates for CYP3A should be included. 
The potency of myricetin to inhibit CYP3A activity in male pigs (no inhibition in 
female pigs) was weak, compared to its potency to inhibit CYP1A EROD. Other 
metabolic reactions that are inhibited by myricetin, includes human CYP3A-medi-
ated metabolism of the drugs triazolam (Moltke et al., 2012), quinidine (Ho et al., 
2001) and testosterone (Kimura et al., 2010). 
In human microsomes, rutin inhibited CYP3A-mediated metabolism of steroids 
such as testosterone as well as the drugs quinidine (Ring et al. 1994). In this study, 
no inhibition by rutin was observed.  
 
Phenolic acids, used in the present study did not modify either CYP1A or CYP3A 
activities. Previous findings suggested that some phenolic acids are metabolized by 
CYP450 (Martignoni et al., 2006). In this case, the competitive inhibition of 
CYP450 substrate metabolism would be expected. However, no inhibition was ob-
served. More studies are needed to identify the role of phenolic acids in the regula-
tion of CYP450 activity. 
The risks for berry component-drug interactions are not yet well documented. 
Further research is needed to assess the degree and mode of possible interactions. 
In such research, both in vivo and in vitro studies need to be included. Gender-
related differences in CYP450 activity observed in the present and previous studies 
(Kojima & Degawa, 2013; Rasmussen et al., 2012; Rasmussen et al., 2011; Skaanild 
& Friis, 1999) should be taken into account when designing future studies on inter-
actions between food/feed components and CYP450 activity.  
The results from the present study contribute to further understanding on the in-
teractions between the dietary phenolic components, quercetin, myricetin and iso-
rhamnetin and, CYP450-mediated metabolism. Further investigations are needed to 
determine physiological significance of this inhibition and its relevance for food-
drug interactions in humans. 
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6 Conclusions 
 
The study suggests that individual components in bilberry fruits have an inhibi-
tory effect on CYP1A and CYP3A activity. The mode and degree of this inhibition 
differed between male and female. Further research is needed to elucidate exact 
mechanism and physiological significance of the interaction between phenolic com-
pounds and CYP450-mediated hepatic metabolism. 
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9 Appendix: Popular summary 
 
Are bilberry fruit and its phenolic constituent´s ca-
pable of changing drug metabolism and, thus the ef-
fect of drugs?   
 
An increased awareness about food-drug interactions may reduce unwanted side-
effects and severe complications such as those arising from a simultaneous intake 
of drugs with food/supplements. In this study, bilberry fruit and phenolic compo-
nents from bilberry fruit was investigated for their potential to interact with the ma-
jor drug metabolizing enzyme system, cytochrome P450 (CYP450). Interactions be-
tween CYP450 activity (activation/deactivation of drugs) and certain food or food 
components may result in an increased (or decreased) bioavailability of the drug and 
thus, an increased (or decreased) drug effect.  
 
The most known example of FDI is that of grapefruit and the CYP450 isoform 
3A (CYP3A), which is the quantitatively most important CYP450. Grapefruit inter-
act with almost all drugs and may increase bioavailability of the drug and, thus the 
effect of the drug as much as five-fold. Active components and mechanisms of FDI 
are not yet fully understood. However, individual dietary flavonoids, which are most 
known for their many, health beneficial effects, have demonstrated potency to in-
hibit CYP450 and, should thus also be seen as a threat. 
 
Pig is a good and commonly used animal model for human CYP450 activity and, 
drug metabolism. In this study, hepatic microsomes from pig, was used to study the 
activity of CYP1A and CYP3A in the presence of bilberry extract and its phenolic 
constituents (quercetin, myricetin, isorhamnetin, rutin, p-coumaric acid, caffeic acid 
and gallic acid). Previous studies have showed that gender-related differences in 
CYP450 activity occur in porcine, and in human, even though these results are still 
questioned. In the present experiment, hepatic microsomes from both male and fe-
male pigs were used. 
 
In this study, further evidence on gender-related regulation of CYP450 was 
demonstrated. First, the activity of CYP1A decreased markedly in male but not in 
female in the presence of bilberry extract, while the activity of CYP3A increased in 
male and decreased in female.  
Secondly, individual flavonols (quercetin, myricetin and isorhamnetin) con-
firmed the gender-related differences. Quercetin, the most potent of the inhibitors 
investigated, inhibited CYP1A in male pigs competitively and irreversibly in female 
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pigs. The gender-related pattern of CYP1A inhibition by quercetin might explain 
overall inhibition of male CYP1A by bilberry extract. Previous studies, on human 
CYP1A activity show a lower degree of inhibition by quercetin. Isorhamnetin and 
myricetin inhibited CYP1A in both male and female pigs. These findings are in line 
with those on human CYP1A1 (Chaudhary & Willet, 2006).  
Even though quercetin is a well-known CYP3A inhibitor in human, CYP3A-me-
diated BFC metabolism was not inhibited by quercetin in pig. This implies specie-
related differences in food/feed-drug interactions, in line with previous findings. 
Myricetin was a weak inhibitor of CYP3A activity in male pigs (no inhibition in 
female pigs) compared to its potency to inhibit EROD by CYP1A. No inhibition 
was observed for rutin or any of the phenolic acids which was investigated in pigs 
in this study even though there are published data on such interactions in previous 
literature. 
 
For future studies on interactions between food/feed components and CYP450 
activity, this report recommends to take gender-specific patterns into account. To 
determine physiological significance and relevance for FDI further investigations 
are needed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
